Thyroid Cancer
Specialty Channel

Featured Article
Results from a cohort study on male pesticide applicators found that extended use of pesticides were tied to an increased risk for thyroid cancer.
True or false: Artificial LAN may increase the risk of thyroid cancer?
A real-world study found both vandetanib and cabozantinib to be effective in treating patients with advanced MTC.
Researchers found that artificial light at night may disrupt circadian rhythm, leading to an increased risk of developing thyroid cancer.
Researchers have found a significant increase in the OS of patients with ATC patients from 2000 to 2019, suggesting that advances in treatment have improved survival.
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.

News

Results from a cohort study on male pesticide applicators found that extended use of pesticides were tied to an increased risk for thyroid cancer.
A real-world study found both vandetanib and cabozantinib to be effective in treating patients with advanced MTC.
Researchers found that artificial light at night may disrupt circadian rhythm, leading to an increased risk of developing thyroid cancer.
Researchers have found a significant increase in the OS of patients with ATC patients from 2000 to 2019, suggesting that advances in treatment have improved survival.

Interactive Features

True or false: Artificial LAN may increase the risk of thyroid cancer?
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
Stay in the know.
OncNet Newsletter